evipedia.ai
← Back

Eloralintide for Health & Longevity

Evidence Review created on 09/15/2026 using AI4L / Opus 5

Also known as: LY3841136, LY-3841136

Motivation

Eloralintide is an experimental medicine given as a once-weekly subcutaneous injection. It imitates amylin, a hormone the pancreas releases together with insulin after a meal to signal fullness and to slow the exit of food from the stomach. Interest in it comes from a simple observation: the appetite system has more than one switch, and amylin is a switch that current weight-loss medicines do not press.

Amylin-based treatment is not new. A first copy of the hormone reached pharmacies two decades ago as an add-on for diabetes, but it had to be injected several times a day and its effect on weight was small. Long-acting successors followed. Eloralintide differs from them in being built to act narrowly on a single amylin receptor rather than on a closely related one, a design meant to separate the feeling of fullness from nausea.

This review examines what the published human and laboratory evidence shows about eloralintide: its effects on body weight and related health measures, the adverse events recorded so far, how it has been administered in trials, and where the evidence remains thin or absent.

Benefits - Risks - Protocol - Conclusion

High-level overviews of eloralintide and of the amylin drug class; every eloralintide-specific source listed here was authored or funded by Eli Lilly and Company, the manufacturer, a conflict of interest that runs through the whole eloralintide evidence base.

No content from the six priority experts is listed because none of them has published on eloralintide or on selective amylin receptor agonism; their obesity-pharmacology output is confined to incretin-based drugs (medicines copying gut hormones released after eating, such as semaglutide), which act through a different receptor and are not the subject of this review.

Grokipedia

Eloralintide

Grokipedia’s dedicated entry compiles eloralintide’s receptor selectivity, phase 2 weight-loss results and trial programme in one place, offering a quickly readable orientation before the primary literature.

Examine

No Examine article exists for eloralintide.

Examine.com covers dietary supplements and does not typically cover prescription or investigational pharmaceuticals, and eloralintide is an investigational injectable drug rather than a supplement.

ConsumerLab

No ConsumerLab article exists for eloralintide.

ConsumerLab tests commercially sold supplements and foods and does not typically cover prescription or investigational medications, and eloralintide is an investigational injectable drug that is not sold to consumers.

Systematic Reviews

Systematic reviews and meta-analyses covering eloralintide and the wider amylin-agonist class; only one includes eloralintide itself, and no review yet addresses eloralintide’s own lean-mass loss or long-term safety, so those harms remain unrepresented in the meta-analytic literature.

Mechanism of Action

Amylin is a 37-amino-acid hormone released from pancreatic beta cells alongside insulin after eating. It acts on the area postrema and nucleus tractus solitarius (hindbrain regions that sit outside the blood-brain barrier) to end a meal, slows gastric emptying, and suppresses glucagon, the hormone that raises blood sugar. Amylin has no dedicated receptor: the calcitonin receptor (CTR) pairs with receptor activity-modifying proteins (RAMPs, accessory proteins that change what a receptor prefers to bind) to form the amylin receptors AMY1R, AMY2R and AMY3R.

Eloralintide is a synthetic amylin analogue engineered not to clump the way human amylin does, and acylated with a twenty-carbon fatty diacid so that it binds reversibly to albumin, the main carrier protein in blood. That albumin binding keeps it largely within the circulation, where it reaches the hindbrain sites that lack a blood-brain barrier. In cell assays it activated human AMY1R roughly 12-fold more potently than CTR and 11-fold more than AMY3R (Briere et al., 2025).

Two mechanistic explanations compete for its tolerability. The selectivity account holds that calcitonin-receptor engagement drives nausea rather than fullness, so avoiding it should reduce food intake with less aversion; in rats, eloralintide caused less learned food aversion than cagrilintide. The pharmacokinetic account attributes the same result to exposure shape: an approximately 14-day half-life and slow absorption produce peak-to-trough ratios of 1.28 to 1.38, a nearly flat weekly curve (Bhattachar et al., 2026). Clearance is by peptide breakdown, not by cytochrome P450 enzymes (the liver family that clears most drugs).

Historical Context & Evolution

Amylin was identified in 1987 as the protein forming the amyloid deposits found in the pancreatic islets of people with type 2 diabetes, and was named islet amyloid polypeptide. Its original therapeutic purpose was glucose control, not weight: because people with type 1 diabetes lose amylin along with insulin, replacing it was expected to blunt post-meal glucose spikes. Human amylin aggregates too readily to be given as a drug, so a non-clumping analogue based on rat amylin, pramlintide, was developed and approved in 2005 as an injected add-on to mealtime insulin.

Pramlintide worked, but modestly. It required injection with each meal, carried a boxed warning for severe insulin-related hypoglycemia (dangerously low blood sugar), and produced weight reductions of only a few percent. What redirected the field toward weight was the consistency of that small weight effect and, later, the structural discovery that amylin signals through calcitonin-receptor–RAMP complexes rather than a receptor of its own.

That structural insight made it possible to engineer long-acting analogues and to tune which complex they favor. Cagrilintide, a dual amylin and calcitonin receptor agonist, came first; eloralintide followed with deliberate selectivity for AMY1R. The prevailing reading — that selectivity buys tolerability — is a hypothesis that its own developers describe as unproven, with exposure shape a live alternative explanation (Bhattachar et al., 2026).

Expected Benefits

Evidence grades below reflect the class of evidence behind each item. Only two completed placebo-controlled trials of eloralintide have been published, both funded, run and authored by Eli Lilly and Company: a 12-week phase 1 multiple-ascending-dose study in 100 adults (Bhattachar et al., 2026) and a 48-week phase 2 randomized controlled trial (RCT, a study in which participants are assigned by chance to drug or placebo) in 263 adults (Billings et al., 2025).

High 🟩 🟩 🟩

Body-Weight Reduction

The central effect: once-weekly eloralintide lowers body weight by suppressing food intake through hindbrain fullness signaling. The evidence is two placebo-controlled trials in adults with obesity or overweight — a 12-week phase 1 study and a 48-week phase 2 RCT — with a consistent dose-response in both. The phase 2 population had a mean body mass index (BMI, weight relative to height) of 39.1 kg/m² and was 78% female, so the size of the effect in men is less well characterized. Both trials excluded type 2 diabetes.

Magnitude: At 48 weeks, mean weight change was −9% at 1 mg (95% confidence interval, or CI, the range in which the true value probably lies: −12.6 to −6.3), −12% at 3 mg, −18% at 6 mg, −20% at 9 mg and −20% with 6–9 mg escalation, against −0.4% for placebo; weight loss of 10% or more was reached by 92% of the 6–9 mg group (Billings et al., 2025).

Medium 🟩 🟩

Reduced Central Adiposity with Favorable Fat-to-Lean Ratio

Weight lost on eloralintide is disproportionately fat rather than lean tissue, and it comes off the waist. A dual-energy X-ray absorptiometry substudy (DXA, a scan that separates fat from lean tissue) within the 48-week phase 2 RCT found most of the reduction came from fat mass, at roughly the 3:1 fat-to-lean ratio seen with other effective weight-loss interventions. Evidence is a single trial, and the DXA substudy was a planned subset of about 160 participants rather than the whole cohort, so precision is limited.

Magnitude: Waist circumference fell by up to 17.1 cm in the 6–9 mg escalation group at 48 weeks, and BMI by up to 7.8 kg/m² versus 0.2 kg/m² for placebo (Billings et al., 2025).

Improved Blood Lipids

Total cholesterol, low-density lipoprotein cholesterol (LDL, the particle that deposits cholesterol in artery walls) and non-high-density-lipoprotein cholesterol all fell more with every eloralintide dose than with placebo, while high-density lipoprotein cholesterol (HDL, the particle that carries cholesterol away from tissues) rose with eloralintide and was unchanged on placebo. The effect is most plausibly a consequence of fat loss rather than a direct lipid action. Evidence is one trial, and these were secondary endpoints not adjusted for multiple testing.

Magnitude: Direction is consistently favorable and holds across all six dose arms at 48 weeks; the literature reports no outcome figure for the size of the lipid changes, only that each eloralintide arm exceeded placebo (Billings et al., 2025).

Lower Average Blood Sugar

Glycated hemoglobin (HbA1c, average blood sugar over roughly three months) fell more on eloralintide than on placebo across the dose range, in a population that did not have type 2 diabetes and therefore had limited room to improve. Amylin agonism suppresses post-meal glucagon release, which plausibly contributes independently of weight loss, though the earlier phase 1 study found glucagon lowering inconsistent and dose-unrelated. Evidence is a single 48-week trial with a non-diabetic population.

Magnitude: HbA1c fell by up to 0.38 percentage points (6 mg arm), similar across treatment groups, versus 0.13 percentage points on placebo, over 48 weeks (Billings et al., 2025).

Lower Systemic Inflammation

High-sensitivity C-reactive protein (hsCRP, a blood marker of body-wide inflammation that tracks cardiovascular risk) fell substantially in participants who started with elevated levels. Adipose tissue is a source of the inflammatory signals that drive hsCRP production, so a large reduction in fat mass is the likely mechanism rather than any direct anti-inflammatory action of the drug. Evidence is one trial and an exploratory endpoint; the fall was measured only from elevated baselines.

Magnitude: hsCRP was reduced by up to 64% from elevated baseline values over 48 weeks (Billings et al., 2025).

Lower Blood Pressure

Blood pressure improved alongside the other cardiometabolic measures in the 48-week phase 2 RCT. Weight reduction of the magnitude seen here reliably lowers blood pressure through reduced blood volume, lower sympathetic nervous activity and improved vessel function, so this is best read as a downstream consequence rather than a distinct drug action. Evidence is a single trial, reported as a secondary endpoint without published numbers.

Magnitude: Direction is a reduction, reported across the eloralintide arms relative to placebo at 48 weeks; the literature reports no outcome figure for the size of the blood-pressure change (Billings et al., 2025).

Better Everyday Physical Functioning

Self-reported physical functioning improved on the SF-36v2 physical functioning scale (a standard questionnaire measure of everyday physical capability such as climbing stairs and carrying groceries). This matters more than a laboratory value for people whose reason for losing weight is capability rather than a number. Evidence is a single 48-week trial; the improvement appeared in every dose arm except the lowest, and the measure is self-reported and unblinded to the participant’s own weight change.

Magnitude: Improvement on the SF-36v2 physical functioning score at 48 weeks in all arms except 1 mg; the literature reports no outcome figure for the point change (Billings et al., 2025).

Low 🟩

Gastrointestinal Tolerability Relative to Incretin Drugs ⚠️ Conflicted

The claim that AMY1R selectivity delivers weight loss with less nausea. Phase 1 supported it (nausea 8%); phase 2 did not (64.3% at fixed 6 mg). No head-to-head trial exists. Net reading: tolerability is better only under slow escalation, not intrinsically.

Magnitude: Nausea occurred in 32.7% of all eloralintide participants versus 13.5% on placebo across 48 weeks, falling to 25% under the slowest escalation schedule; no head-to-head comparison with an incretin drug has been published (Billings et al., 2025).

Gastric Emptying Largely Preserved

Unlike amylin and pramlintide, eloralintide appears not to slow stomach emptying persistently. Using acetaminophen absorption as a probe, exposure dipped after the first dose then returned to baseline on continued dosing. Evidence is an uncontrolled substudy in one small phase 1 trial.

Magnitude: Direction is a transient, dose-related slowing after the first dose that resolves on repeat dosing; the literature reports no outcome figure for the change in gastric emptying rate (Bhattachar et al., 2026).

Speculative 🟨

Additive Weight Loss Alongside Incretin Therapy

No human efficacy results for eloralintide combined with an incretin drug have been published. The basis is mechanistic — separate receptors, separate satiety pathways — plus the additive effect seen with a different amylin analogue.

Healthspan Benefits Beyond Weight Itself

No human outcome data exist. The basis is mechanistic extrapolation from the marker changes observed and from what sustained fat loss is known to do; no trial has measured disease events or survival.

Benefit-Modifying Factors

  • Genetic variation in the receptor complex: No pharmacogenetic data exist for eloralintide. Variants in CALCR (the calcitonin receptor gene) and RAMP1–3 (genes for the accessory proteins that create amylin receptors) plausibly alter response, but none has been tested against eloralintide outcomes.

  • Baseline inflammation: The large fall in high-sensitivity C-reactive protein was seen in participants who started with elevated values. Those already in the low-risk range have proportionally less to gain on that marker, though weight response itself appeared independent of baseline inflammation.

  • Baseline body mass index and weight: Trial entrants averaged 39.1 kg/m², well above the 27 kg/m² entry threshold. Percent reductions in leaner participants near that threshold are less well characterized, and absolute kilogram losses are necessarily smaller.

  • Sex: The phase 2 trial was 78% female, and women typically lose more weight than men on any anti-obesity intervention. No male subgroup analysis has been published, so the effect size in men is uncertain.

  • Pre-existing type 2 diabetes: Both published trials excluded type 2 diabetes. Weight loss is consistently smaller in people with diabetes across this drug class, so benefit in that group is unestablished until the dedicated phase 3 diabetes trial reports.

  • Age: Trials enrolled adults aged 18 to 75. At the older end, age-related muscle loss means a given percentage of weight lost carries more functional cost, so the favorable fat-to-lean ratio matters more, and resistance training becomes a larger determinant of net benefit.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Nausea and Vomiting

The dominant adverse effect, and the one that defines how eloralintide must be dosed. It is mechanistic: amylin receptor signaling in the hindbrain sits adjacent to the circuitry that generates nausea. It is strongly dose- and escalation-dependent, mild to moderate in most participants, and it declines when the dose is raised gradually. Both published trials document it. Vomiting was far less frequent than nausea and absent from placebo and the two lowest dose arms.

Magnitude: Nausea in 32.7% of eloralintide participants versus 13.5% on placebo over 48 weeks, peaking at 64.3% in the fixed 6 mg arm and falling to 25% with 3–9 mg escalation; vomiting in 8.2% versus 0% on placebo (Billings et al., 2025); nausea 8% and vomiting 4% over 12 weeks in phase 1 (Bhattachar et al., 2026).

Fatigue

Consistently reported in both trials and, unlike the gastrointestinal effects, not obviously explained by the drug’s known mechanism. It tracked dose, was most common in the highest-exposure arms, and was mild to moderate in most cases. Rates fell under slower escalation but stayed above placebo in every dose arm except the lowest. Whether it reflects energy deficit, the drug itself, or both is unresolved.

Magnitude: Fatigue in 26.9% of pooled eloralintide participants versus 11.5% on placebo over 48 weeks, reaching 45.8% in the 6–9 mg arm (Billings et al., 2025); 11% over 12 weeks in phase 1 (Bhattachar et al., 2026).

Adverse-Event-Driven Discontinuation

A substantial minority of participants stopped the drug because of side effects. The rate is dose-driven: the fixed 6 mg arm, which combined a high dose with no escalation, was the worst, and the phase 1 trial, which escalated no dose at all, lost 13 of its 100 participants. Documented in both published trials. This is the practical ceiling on the drug’s usefulness, since a treatment that is stopped delivers no benefit.

Magnitude: Discontinuation for adverse events in 10% of eloralintide participants overall and 21% in the fixed 6 mg arm, versus 8% on placebo, over 48 weeks (Billings et al., 2025); 13 of 100 participants discontinued for adverse events in the phase 1 trial, which used no escalation (Bhattachar et al., 2026).

Constipation and Diarrhea

Both directions of altered bowel habit occurred more often than on placebo, reflecting amylin’s action on gut motility and the reduced food and fiber intake that follows appetite suppression. Reported in both published trials. Severity was mild to moderate and no case led to a serious adverse event, but the effects persist for as long as dosing continues rather than resolving once the dose stops rising.

Magnitude: Constipation and diarrhea each in about 15% of eloralintide participants over 48 weeks, versus 5.8% and 9.6% respectively on placebo (Billings et al., 2025); diarrhea in 10% over 12 weeks in phase 1 (Bhattachar et al., 2026).

Medium 🟥 🟥

Appetite Suppression Severe Enough to Compromise Intake

Decreased appetite was the single most common treatment-emergent adverse event in the phase 1 trial. It is the therapeutic mechanism, but at the upper doses it can reduce intake below what is needed for adequate protein, fiber and micronutrients, which in turn compounds muscle loss and constipation. Evidence is one trial reporting it as a distinct adverse event; no trial has measured resulting nutrient intake or deficiency.

Magnitude: Decreased appetite reported by 19% of eloralintide participants over 12 weeks (Bhattachar et al., 2026).

Headache

Reported at rates that rose numerically with dose in the phase 1 trial, where all cases were mild and none led to dose modification. Plausible contributors include dehydration and reduced energy intake rather than a specific drug action. Evidence is a single small trial.

Magnitude: Headache in 12% of eloralintide participants over 12 weeks (Bhattachar et al., 2026).

Injection-Site Reactions

Local redness, itching or swelling at the subcutaneous injection site, more frequent at higher doses in the phase 1 trial. All were mild and none required a dose change. This is expected for an acylated peptide given weekly, and evidence is limited to that one trial.

Magnitude: Direction is a dose-related increase in local reactions, all mild and none prompting dose modification over 12 weeks; the literature reports no outcome figure for their incidence (Bhattachar et al., 2026).

Low 🟥

Loss of Lean Mass ⚠️ Conflicted

Appetite suppression reduces muscle as well as fat, a documented harm across obesity drugs generally. The eloralintide DXA substudy pointed the other way, showing preferential fat loss at roughly 3:1. Net reading: the eloralintide data are reassuring but come from one small subset, so the class concern is not retired.

Magnitude: Across obesity drugs generally, the most potent agent reduced lean mass by 8.3% (Nong et al., 2026); no eloralintide-specific lean-mass figure has been published, only the reported 3:1 fat-to-lean ratio in a subset (Billings et al., 2025).

Mood-related events were observed with eloralintide in the phase 1 trial but were not quantified or separated from the effects of rapid weight loss itself. The evidence is an uncontrolled observation in 100 participants over 12 weeks.

Magnitude: Direction is an observed occurrence of mood-related events alongside fatigue in the treated cohort; the literature reports no outcome figure for their frequency (Bhattachar et al., 2026).

Weight Regain After Stopping

No eloralintide discontinuation data exist. Across the obesity-drug literature, weight returns when appetite-suppressing treatment stops, and regained weight is more fat than the lean tissue that was lost.

Magnitude: Direction is regain after treatment withdrawal, established for obesity drugs as a class rather than for eloralintide; the literature reports no outcome figure for eloralintide (Nong et al., 2026).

Gallstones and Gallbladder Inflammation

Large, rapid weight loss raises the concentration of cholesterol in bile and slows gallbladder emptying, promoting stones. No eloralintide trial has reported gallbladder events. The evidence is indirect: pooled trials of other weight-loss drugs producing comparable loss show a clear excess.

Magnitude: In trials of incretin drugs used for weight loss, gallbladder or biliary (bile duct) disease was 2.29 times more frequent than on comparator (95% CI 1.64 to 3.18), rising with higher doses and longer exposure; no eloralintide-specific figure exists (He et al., 2022).

Speculative 🟨

Severe Hypoglycemia with Insulin or Insulin Secretagogues

No controlled data exist for eloralintide, studied only in people without type 2 diabetes. Secretagogues prompt the pancreas to release insulin; the basis is pramlintide’s labelled boxed warning plus shared mechanism.

Anti-Drug Antibodies Reducing Effect

No immunogenicity results have been published for eloralintide. The basis is mechanistic and class-based: engineered peptides can provoke antibodies that neutralize activity or cause reactions, which would show as fading response.

Bone Mineral Density Loss

No bone measurements have been reported for eloralintide. The basis is mechanistic and class-based: a large sustained energy deficit reduces bone mass alongside fat and muscle, an effect no amylin-agonist trial has yet measured.

Risk-Modifying Factors

  • Genetic variation: No pharmacogenetic data exist. Clearance is by peptide breakdown, not by cytochrome P450 enzymes, so variants in the genes for those drug-clearing enzymes, such as CYP2C9 or CYP2D6, should not alter exposure.

  • Baseline kidney and liver function: Dedicated trials in renal and hepatic impairment are still running, so exposure in those states is unquantified. Until they report, impaired clearance and higher exposure — hence more nausea and fatigue — cannot be excluded.

  • Sex: With 78% female enrolment in phase 2 and 29% in phase 1, sex-specific adverse-event rates are poorly resolved. No sex difference in tolerability has been reported, but neither trial was powered to detect one.

  • Pre-existing conditions: Gastroparesis (delayed stomach emptying), inflammatory bowel disease and chronic constipation amplify the gastrointestinal effects. Eating disorders are aggravated by pharmacological appetite suppression. Insulin-treated diabetes adds hypoglycemia risk that the published trials, which excluded diabetes, cannot quantify.

  • Age: Older adults carry less muscle reserve, so the same percentage weight loss costs more function, and they tolerate dehydration from vomiting or diarrhea less well. Trials enrolled up to age 75; above that, no data exist.

  • Baseline biomarkers: A low starting high-sensitivity C-reactive protein, normal blood pressure and normal lipids mean less to gain, while the adverse events remain unchanged, shifting the balance unfavorably for metabolically healthy individuals.

Key Interactions & Contraindications

  • Insulin and insulin secretagogues (glimepiride, glipizide, repaglinide): Caution — additive glucose lowering risks severe hypoglycemia, the harm that carries a boxed warning for pramlintide. Mitigation: insulin or secretagogue dose reduction before starting, with close glucose monitoring during escalation.

  • Incretin drugs (semaglutide, tirzepatide, liraglutide): Caution — additive weight loss but also additive nausea, vomiting and fatigue, as seen when a different amylin analogue was combined with semaglutide. Mitigation: escalation of one agent at a time, holding the dose at the first sign of intolerance.

  • Narrow-therapeutic-index oral drugs (warfarin, levothyroxine, digoxin, some antiseizure drugs): Monitor — any change in gastric emptying alters absorption timing. Eloralintide’s effect on emptying appears transient. Mitigation: weekly drug levels, or INR (a blood-clotting time measure) for warfarin, through the first month.

  • Combined oral contraceptives (ethinyl estradiol, levonorgestrel): Monitor — slowed gastric emptying could reduce hormone absorption and so contraceptive reliability; the dedicated interaction study has not yet reported. Mitigation: a non-oral contraceptive method avoids the question during active dose escalation.

  • Over-the-counter analgesics (acetaminophen, ibuprofen, naproxen): Monitor — acetaminophen absorption was modestly slowed after the first eloralintide dose before returning to baseline. Mitigation: slower onset of pain relief is expected in week one; no dose change is indicated.

  • Over-the-counter sedating antihistamines and sleep aids (diphenhydramine, doxylamine): Caution — additive daytime fatigue, already reported by more than a quarter of treated participants. Mitigation: avoidance during dose escalation, when fatigue rates peak.

  • Over-the-counter antidiarrheals and laxatives (loperamide, bisacodyl, senna): Caution — bowel habit swings in both directions on eloralintide, so a fixed self-treatment regimen can overshoot. Mitigation: as-needed use only, with weekly reassessment.

  • Glucose-lowering supplements (berberine, chromium picolinate, bitter melon, cinnamon extract): Caution — additive glucose lowering, relevant only for those also taking insulin or a secretagogue. Mitigation: glucose monitoring, rather than combining these supplements without measurement.

  • Bulk-forming and appetite-suppressing supplements (psyllium, glucomannan, 5-HTP or 5-hydroxytryptophan, a serotonin building block): Caution — additive fullness and additive constipation with an agent that already reduces intake. Mitigation: dosing separated by several hours, with raised fluid intake alongside any fiber.

  • Prolonged fasting, very-low-calorie and ketogenic regimens: Caution — layering deliberate restriction onto pharmacological appetite suppression compounds energy deficit, lean-mass loss and fatigue. Mitigation: priority on protein and resistance training over further caloric restriction.

  • Alcohol: Caution — additive nausea, dehydration and fatigue, and empty calories that work against the intervention’s purpose. Mitigation: avoidance on the injection day and during dose escalation.

Populations who should avoid Eloralintide:

  • Anyone outside a clinical trial — eloralintide is investigational and unapproved, so no legitimate supply exists
  • People with type 1 diabetes, and insulin-treated type 2 diabetes without close specialist supervision
  • People who are pregnant, trying to conceive, or breastfeeding
  • People with a current or past eating disorder (anorexia nervosa, bulimia nervosa, binge-eating disorder)
  • People with established gastroparesis or another significant gastrointestinal motility disorder
  • People with severe renal impairment (estimated glomerular filtration rate, or eGFR, a measure of kidney filtering, below 30 mL/min/1.73 m²) or on dialysis
  • People with severe hepatic impairment (Child-Pugh Class C)
  • People with a myocardial infarction (heart attack), stroke, coronary revascularization, unstable angina or heart-failure hospitalization within the prior 90 days
  • People with New York Heart Association (NYHA) Class IV heart failure
  • People with a body mass index below 27 kg/m², or below 30 kg/m² without a weight-related condition
  • People under 18 years of age

Risk Mitigation Strategies

  • Slow, stepwise dose escalation: Mitigates nausea, vomiting and discontinuation. Stepping 3 mg to 6 mg at week 4 and to 9 mg at week 8 cut nausea to 25% against 64.3% for a fixed 6 mg start.

  • Hold rather than push at first intolerance: Mitigates adverse-event-driven discontinuation, which reached 21% in the arm combining a high dose with no escalation. Staying at the current dose an extra two to four weeks costs little.

  • Deliberate protein intake: Mitigates lean-mass loss compounded by appetite suppression. Roughly 1.2–1.6 g of protein per kilogram of reference body weight daily, prioritized within a shrinking total intake, is the standard target during pharmacological weight loss.

  • Resistance training two to three times weekly: Mitigates loss of muscle and of everyday physical function. Progressive loading is the only intervention shown to preserve lean mass during a large energy deficit, and it also counters age-related muscle loss.

  • Fluid and fiber management: Mitigates constipation and the dehydration that follows vomiting or diarrhea. Two to three litres of fluid daily and 25–35 g of fiber, raised gradually, address the reduced food volume that drives both.

  • Reduce insulin or secretagogue dose before the first injection: Mitigates severe hypoglycemia, the class harm carrying a boxed warning for pramlintide. Reductions are made pre-emptively with glucose monitoring, not after a hypoglycemic event occurs.

  • Rotate injection sites weekly: Mitigates the dose-related local reactions seen in phase 1. Alternating abdomen, thigh and upper arm across consecutive weekly doses prevents repeated trauma to one area of subcutaneous tissue.

  • Schedule around the fatigue peak: Mitigates the 26.9% fatigue rate, highest during escalation. Injecting on a day before a lighter two days, and avoiding concurrent sedating agents or alcohol, limits functional disruption.

  • Baseline and interval laboratory monitoring: Mitigates undetected nutritional depletion and unmasked kidney or liver effects. A full panel before the first dose, repeated at weeks 12 and 24, then every six months, catches silent drift.

Therapeutic Protocol

  • No established practitioner protocol exists: Eloralintide is investigational, so no clinic has a standing regimen. What follows is the regimen used by the trial investigators — Billings, Bays and colleagues at 46 United States centres.

  • Standard regimen: Once-weekly subcutaneous injection, escalated 3 mg to 6 mg at week 4 and to 9 mg at week 8, continued to week 48. This schedule delivered 16.4% weight loss with 25% nausea.

  • Competing approach — maximum efficacy: A 6 mg start with a step to 9 mg at week 20 produced 19.9% weight loss but 45.8% fatigue. Neither approach is the default; the trade-off is efficacy against tolerability.

  • Competing approach — minimum dose: Fixed 1 mg or 3 mg weekly, with no escalation, produced 9% and 12% weight loss and adverse-event rates statistically indistinguishable from placebo, a reasonable target where tolerability outweighs maximal loss.

  • Time of day: No trial has compared dosing times. With an approximately 14-day half-life and a nearly flat weekly concentration curve, time of day is pharmacologically irrelevant; consistency of the weekly day matters more than the hour.

  • Half-life: Approximately 14 days, with slow absorption from the subcutaneous depot. Steady state is therefore reached only after several weeks, meaning the full effect of any dose step is not visible for roughly a month.

  • Single versus split dosing: A single weekly injection. Peak-to-trough ratios of 1.28 to 1.38 mean concentrations barely fluctuate between doses, so splitting would flatten an already flat curve while doubling injections.

  • Genetic polymorphisms: No pharmacogenetic dosing guidance exists. CALCR and RAMP1–3 variants are the mechanistically plausible candidates, and CYP2C9, CYP2D6 and similar metabolizing-enzyme variants are irrelevant because clearance is by peptide breakdown.

  • Sex: No sex-specific dosing was used in either trial. Because women constituted 78% of the phase 2 cohort and typically lose more weight on any intervention, the published dose-response curve may overstate what men achieve.

  • Age: Trials enrolled adults aged 18 to 75, with no age-based dose adjustment. At the older end, slower escalation is the conservative choice because dehydration and muscle loss are less well tolerated.

  • Baseline biomarkers: Higher starting body mass index, elevated high-sensitivity C-reactive protein and dyslipidemia (abnormal blood fats) predict larger measurable gains. Baseline glycated hemoglobin was normal in both trials, so its value as a response predictor is untested.

  • Pre-existing conditions: Type 2 diabetes, moderate or severe kidney impairment and hepatic impairment were excluded from both published trials. Dosing in those states is under study and currently unguided by any published exposure data.

Discontinuation & Cycling

  • Intended duration: Framed as ongoing rather than time-limited. Obesity is treated as a chronic condition across this drug class, and the phase 3 programme runs 64 to 75 weeks with a two-year extension, implying indefinite use rather than a course.

  • Withdrawal effects: None reported. Amylin agonism produces no physical dependence and there is no rebound syndrome; what returns is appetite, and with it the pre-treatment intake pattern that produced the original weight.

  • Weight regain on stopping: The expected consequence, and the reason discontinuation is not neutral. No eloralintide-specific regain data are published; across obesity drugs, regained weight is proportionally more fat than the lean tissue lost.

  • Tapering: No taper protocol has been studied or is mechanistically required. With an approximately 14-day half-life, exposure declines over roughly two months after the last injection, which is itself a gradual offset.

  • Cycling: Not studied and not supported. No tolerance to the weight effect appeared over 48 weeks of continuous dosing, so the usual rationale for cycling — restoring a fading response — does not apply.

  • Stopping for intolerance: Distinct from planned discontinuation. Because adverse events are dose-driven, stepping down to a previously tolerated dose is the studied alternative to stopping outright, and the lower doses retained meaningful effect.

Sourcing and Quality

  • No legitimate consumer supply exists: Eloralintide is investigational and unapproved everywhere. The only authorized material is manufacturer-supplied trial drug, obtained by enrolling in one of the ongoing studies. There is no prescription route and no pharmacy source.

  • Grey-market peptide vendors are not a source: Sites selling “research grade” eloralintide operate outside pharmaceutical regulation. Identity, purity, sterility, endotoxin content and actual peptide mass are unverified, and the acylated structure is difficult to synthesize correctly.

  • Compounding pharmacies cannot lawfully supply it: Compounding requires an approved active ingredient or a documented shortage of one. Neither applies to an unapproved investigational molecule, so any compounded offering is operating outside that framework.

  • What third-party testing would need to show: For any peptide, a certificate of analysis from an independent laboratory covering mass-spectrometry identity, purity above 98%, sterility and endotoxin limits. Vendor-issued certificates are not third-party testing.

  • Formulation: A sterile aqueous solution for subcutaneous injection, requiring refrigerated storage and protection from freezing. Freeze-dried powder sold for self-reconstitution is not the trial formulation and introduces sterility and concentration errors.

Practical Considerations

  • Time to effect: Appetite suppression begins within the first weeks, but the approximately 14-day half-life means steady state takes about a month per dose step. Meaningful weight change appears by week 12; the full 48-week effect accrues progressively.

  • Common pitfall — escalating too fast: The single largest determinant of whether treatment is tolerated. A fixed 6 mg start produced 64.3% nausea and 21% discontinuation, while stepwise escalation to the same and higher doses cut both substantially.

  • Common pitfall — treating it as a substitute for protein and training: Appetite suppression reduces total intake indiscriminately. Without deliberate protein intake and resistance work, the favorable fat-to-lean ratio seen in the DXA substudy is unlikely to be reproduced.

  • Common pitfall — assuming incretin-equivalent benefits: Semaglutide and tirzepatide carry cardiovascular outcome data that eloralintide does not. Weight loss of similar size does not establish equivalent protection against heart attack, heart failure or death.

  • Regulatory status: Investigational in every jurisdiction, with no marketing approval anywhere. Phase 3 trials began in early 2026 and the earliest of them completes in 2028, so approval, if it comes, is years away.

  • Cost and accessibility: Currently obtainable only by trial enrolment, which is free but geographically limited and governed by strict eligibility criteria. Approved injectable obesity drugs in this class run to several hundred dollars monthly.

  • Payer incentives as a source of bias: Insurers and national health systems have a clear financial incentive to favor cheaper older agents over costly new injectables, a structural bias worth keeping in view when reading coverage policies and guideline recommendations.

Interaction with Foundational Habits

  • Sleep: Indirect and generally favorable. Weight loss of the magnitude observed reduces obstructive sleep apnea severity, which a dedicated phase 3 trial is now testing directly. Working against this, the fatigue reported by 26.9% of participants can encourage daytime napping that fragments night-time sleep during escalation.

  • Nutrition: Directly blunting — the drug works by reducing intake, which lowers protein, fiber and micronutrient consumption in parallel with calories. Practically, protein and vegetables are eaten first within a smaller total, fiber is raised gradually against constipation, and high-fat meals are limited during escalation because they worsen nausea.

  • Exercise: Potentiating in one direction, at risk in the other. Lower body weight makes aerobic and load-bearing work easier and less painful, which the knee osteoarthritis trial is examining. But rapid loss without resistance training costs muscle, so two to three progressive sessions weekly are the counterweight.

  • Stress management: Indirect, with no measured effect on cortisol or the stress response. The relevant interaction is behavioral: pharmacological appetite suppression removes eating as a stress outlet without replacing it, so the underlying stressor surfaces. Mood-related events reported in phase 1 make this worth tracking deliberately rather than assuming it resolves itself.

Monitoring Protocol & Defining Success

Before the first injection, a baseline panel establishes the metabolic starting point and screens for the conditions that make eloralintide inadvisable: body weight and waist circumference, blood pressure, a full lipid panel, glycated hemoglobin, high-sensitivity C-reactive protein, a comprehensive metabolic panel covering kidney and liver measures, and body composition by scan where available. Ongoing monitoring follows the escalation schedule rather than the calendar: tolerability and weight are reviewed at weeks 4 and 8 as doses step up, the full laboratory panel is repeated at week 12 and week 24, and thereafter every six months while dosing continues. Body composition is reassessed at six and twelve months, because the fat-to-lean ratio, not the scale reading, is what determines whether the weight lost is the weight worth losing.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Body weight (percent change) −10% or more from baseline by 48 weeks Primary effect; defines response Weigh at the same time of day, fasted, on the same scale; weekly trend matters more than any single reading
Waist circumference Below 94 cm (men), below 80 cm (women) Tracks central fat, the metabolically active depot Measured at the iliac crest at end of a normal breath; fell up to 17.1 cm in trial; conventional cut-offs are far looser, 102 cm (men) and 88 cm (women)
Lean body mass (scan) No decline beyond 25% of total weight lost Distinguishes useful fat loss from muscle loss Measured by dual-energy X-ray absorptiometry (DXA, a scan separating fat from lean tissue); same machine each time
Glycated hemoglobin 4.8–5.3% Detects drift in average blood sugar Glycated hemoglobin (HbA1c) reflects roughly three months; no fasting needed; conventional range extends to 5.6%
Fasting insulin 2–5 µIU/mL Detects insulin resistance improving or persisting Fasting 10–12 hours; pair with fasting glucose to derive insulin resistance; conventional labs flag only above 25 µIU/mL
Apolipoprotein B Below 80 mg/dL, below 60 mg/dL if high risk Counts atherogenic particles better than cholesterol alone Apolipoprotein B (ApoB) is the protein on each artery-damaging particle; non-fasting acceptable; often not in standard panels
Lipid panel Triglycerides below 80 mg/dL; HDL above 55 mg/dL Tracks the lipid improvements seen in trial High-density lipoprotein (HDL) carries cholesterol away from tissue; fast 12 hours for triglycerides; conventional cut-offs are far looser, triglycerides below 150 mg/dL and HDL above 40 mg/dL (men) or 50 mg/dL (women)
High-sensitivity C-reactive protein Below 0.5 mg/L Tracks inflammation falling with fat loss High-sensitivity C-reactive protein (hsCRP) rises with any infection; repeat before acting; conventional cut-off is 3.0 mg/L
Estimated glomerular filtration rate Above 90 mL/min/1.73 m² Kidney handling of the drug is not yet characterized Estimated glomerular filtration rate (eGFR) estimates kidney filtering; avoid heavy exercise and high protein for 48 hours beforehand; conventional labs flag only below 60 mL/min/1.73 m²
Liver enzymes (ALT) Below 25 U/L (men), below 20 U/L (women) Hepatic impairment studies are still running Alanine aminotransferase (ALT) leaks from liver cells when stressed; conventional upper limit near 40 U/L is far less sensitive
Vitamin B12 and ferritin B12 above 500 pg/mL; ferritin 50–150 ng/mL Reduced intake can deplete both silently Ferritin rises with inflammation, so read alongside high-sensitivity C-reactive protein; fasting not required; conventional ranges start much lower, B12 at 200 pg/mL and ferritin at 15 ng/mL
Blood pressure Below 120/80 mmHg Tracks the reduction reported in trial Seated, five minutes rest, arm supported; average three readings; measure before the weekly injection

Qualitative markers worth tracking alongside the laboratory values:

  • Appetite and fullness — how much smaller portions have become, and whether food preoccupation has eased
  • Nausea severity and timing relative to the injection day, recorded as a simple daily score during escalation
  • Energy and fatigue, separated where possible into physical tiredness and mental flatness
  • Everyday physical capability — stairs, carrying, floor-to-stand, walking distance before discomfort
  • Sleep quality and any change in snoring or witnessed breathing pauses
  • Mood and motivation, given the mood-related events recorded in early trials
  • Bowel regularity in both directions, since constipation and diarrhea occurred at similar rates

Emerging Research

  • ENLIGHTEN-1, the pivotal monotherapy trial: NCT07321886 randomizes 1,980 adults with obesity or overweight without type 2 diabetes across four doses against placebo, with percent weight change at week 64 as the primary endpoint and fat mass as a secondary. Completes 2030.

  • ENLIGHTEN-2, the diabetes question: NCT07282600 tests 1,035 adults with obesity or overweight and type 2 diabetes, the population both published trials excluded. Weight loss is consistently smaller in diabetes across this class, so this trial could weaken the headline efficacy figure.

  • ENLIGHTEN-6, the incretin add-on test: NCT07392190 enrols 900 adults whose obesity persists on a weekly incretin drug, adding eloralintide or placebo. This addresses the most commercially significant claim — that a selective amylin agent complements rather than duplicates incretin therapy.

  • ENLIGHTEN-3, sleep apnea: NCT07369011 enrols 800 adults with moderate to severe obstructive sleep apnea, with apnea-hypopnea index (AHI, breathing interruptions per hour of sleep) alongside weight as co-primary endpoints. A hard functional endpoint rather than a marker.

  • ENLIGHTEN-4, knee osteoarthritis pain: NCT07353931 enrols 900 adults, with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, a validated joint pain and function questionnaire) pain subscale as a co-primary endpoint. Tests whether weight loss translates into measurable symptom relief.

  • Combination with tirzepatide in diabetes: NCT06603571 is a 367-participant phase 2 trial of eloralintide and tirzepatide alone or together. Combination data will show whether the additive gastrointestinal burden seen with other amylin-incretin pairings also appears here.

  • Kidney and liver exposure studies: NCT07426380 in renal impairment and NCT07401862 in hepatic impairment measure drug exposure in the organ-impaired states that both published trials excluded. Results could restrict use or reassure.

  • Contraceptive interaction study: NCT07808060 measures ethinyl estradiol and levonorgestrel exposure in 34 female participants on eloralintide, resolving whether oral contraceptive absorption is affected in a trial population that was predominantly female.

  • The unresolved selectivity-versus-exposure question: Whether tolerability comes from AMY1R selectivity or from flat weekly exposure remains undecided; the comparison that would settle it requires agents differing in one dimension at a time (Fischer & Borner, 2026).

  • Where the class-level meta-analytic evidence is thinnest: Current network meta-analyses rate amylin-agonist evidence as sparse and low-certainty, with no cardiovascular outcome trial for any selective amylin agent, so the durability and hard-endpoint case remains entirely open (Kamrul-Hasan et al., 2026).

Conclusion

Eloralintide is an experimental once-weekly injection that copies amylin, the fullness hormone the pancreas releases with insulin after a meal. Unlike the widely used weight-loss injections, it acts on a different appetite pathway and was deliberately built to engage one amylin receptor while avoiding a closely related one, on the theory that the avoided receptor is what causes nausea.

The evidence so far is genuinely striking in size and genuinely narrow in scope. Two placebo-controlled trials, one brief and one running most of a year, show large weight reduction that grows with the dose, with waist, blood fats, average blood sugar, inflammation, blood pressure and everyday physical capability all moving favorably, and with a body-composition scan suggesting most of what is lost is fat rather than muscle. Against that, nausea, fatigue, altered bowel habit and a notable rate of stopping treatment all rise with dose, and the promised tolerability advantage held only when the dose was raised slowly.

Three limits deserve weight. Every published study was funded, conducted and written by the manufacturer. No trial has followed anyone beyond about a year, so durability, regain and long-term safety are unknown. And the drug has never been compared head-to-head with the established alternatives, which carry heart-protection evidence it does not. The claim of a better-tolerated route to comparable weight loss is plausible and not yet settled.

Top - Benefits - Risks - Protocol